Pfizer (PFE) Net Income towards Common Stockholders (2016 - 2025)
Historic Net Income towards Common Stockholders for Pfizer (PFE) over the last 17 years, with Q2 2025 value amounting to $25.0 million.
- Pfizer's Net Income towards Common Stockholders rose 4705.88% to $25.0 million in Q2 2025 from the same period last year, while for Sep 2025 it was $25.0 million, marking a year-over-year increase of 21363.64%. This contributed to the annual value of $11.0 million for FY2024, which is 17333.33% up from last year.
- According to the latest figures from Q2 2025, Pfizer's Net Income towards Common Stockholders is $25.0 million, which was up 4705.88% from -$8.0 million recorded in Q3 2024.
- In the past 5 years, Pfizer's Net Income towards Common Stockholders ranged from a high of $34.0 million in Q3 2022 and a low of -$236.0 million during Q3 2021
- In the last 5 years, Pfizer's Net Income towards Common Stockholders had a median value of -$3.5 million in 2023 and averaged -$16.4 million.
- As far as peak fluctuations go, Pfizer's Net Income towards Common Stockholders crashed by 100000.0% in 2022, and later skyrocketed by 95000.0% in 2024.
- Quarter analysis of 5 years shows Pfizer's Net Income towards Common Stockholders stood at -$13.0 million in 2021, then crashed by 61.54% to -$21.0 million in 2022, then decreased by 23.81% to -$26.0 million in 2023, then skyrocketed by 69.23% to -$8.0 million in 2024, then skyrocketed by 412.5% to $25.0 million in 2025.
- Its Net Income towards Common Stockholders was $25.0 million in Q2 2025, compared to -$8.0 million in Q3 2024 and $17.0 million in Q2 2024.